Joohee Kim, MD
Endocrinology, Diabetes & Metabolism · Shoreline, WANPI 1720044647
Payments from drug & device makers
Across 378 payments — averaging $27.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- Amgen$915
- Dexcom, Inc.$557
- Boehringer Ingelheim$546
- Tandem Diabetes Care, Inc.$541
- plus $6K from 44 others
What the payments were for
- Speaking & faculty fees$3003%
- Food & beverage$10,02196%
- Education$1061%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 Insulin Pump with Control-IQ$443
- Ozempic$375
- TEPEZZA$273
- Omnipod$203
- FREESTYLE LIBRE 3$149
- AFREZZA$140
- VOQUEZNA$129
- Tymlos$125
- RYBELSUS$125
- UNITY DIABETES MANAGEMENT SYSTEM$125
- TZIELD$125
- JARDIANCE$123
- LOKELMA$122
- Yorvipath$121
- DEXCOM G6 TRANSMITTER$115
- FARXIGA$100
How this compares
$10,427 in reported general payments places this provider in the 70th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 169 | $256,593 |
| TrulicityDulaglutide | 91 | $149,809 |
| FarxigaDapagliflozin Propanediol | 111 | $96,476 |
| JardianceEmpagliflozin | 75 | $81,065 |
| JanuviaSitagliptin Phosphate | 30 | $35,114 |
| TymlosAbaloparatide | 11 | $28,750 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $28,314 |
| TradjentaLinagliptin | 27 | $25,688 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $24,462 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $24,158 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $22,092 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 24 | $21,982 |
| Humalog Kwikpen U-100Insulin Lispro | 61 | $21,528 |
| ProliaDenosumab | 11 | $18,389 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 32 | $18,279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,048 | $256,593169 claims |
| Lilly USA, LLCTrulicity, Humalog | $300 | $150,819103 claims |
| Boehringer IngelheimJardiance, Tradjenta | $546 | $106,753102 claims |
| AstraZenecaFarxiga | $1,229 | $96,476111 claims |
| MerckJanuvia, Janumet Xr | $123 | $57,09654 claims |
| Radius Health, Inc.Tymlos | $241 | $28,75011 claims |
| AmgenProlia | $915 | $18,38911 claims |
| Johnson & JohnsonInvokana | $165 | $7,50113 claims |
| Sanofi-aventis U.S. LLCLantus | $531 | $2,49511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
Other endocrinology, diabetes & metabolism in Shoreline
- Ronald BrazgRenton$17.9M
- Frances BroylesSeattle$5.6M
- Leslie KlaffRenton$2.8M
- Carla GreenbaumSeattle$2.6M
- Irl HirschSeattle$2.4M
- William HagopianSeattle$2.1M
- Carol WyshamSpokane$1.6M
- Michael SchwartzSeattle$1.3M
- Michael ShannonLacey$698K
- Lynn KohlmeierSpokane$518K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.